Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Common Equity (2019 - 2025)

Burning Rock Biotech has reported Common Equity over the past 7 years, most recently at $75.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 6.67% year-over-year to $75.5 million; the TTM value through Dec 2025 reached $75.5 million, down 6.67%, while the annual FY2025 figure was $76.5 million, 3.81% down from the prior year.
  • Common Equity for Q4 2025 was $75.5 million at Burning Rock Biotech, down from $80.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $288.6 million in Q4 2021 and troughed at $75.5 million in Q4 2025.
  • A 5-year average of $142.9 million and a median of $106.7 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 43.57% in 2022 and later fell 6.67% in 2025.
  • Year by year, Common Equity stood at $288.6 million in 2021, then tumbled by 43.57% to $162.9 million in 2022, then tumbled by 34.47% to $106.7 million in 2023, then decreased by 24.23% to $80.9 million in 2024, then fell by 6.67% to $75.5 million in 2025.
  • Business Quant data shows Common Equity for BNR at $75.5 million in Q4 2025, $80.9 million in Q4 2024, and $106.7 million in Q4 2023.